Path AI buys Poplar Healthcare; Happify launches PDTx for mental health; Delta COVID variant update

Invent Health with Dr. Archana Dubey and Bambi Francisco Roizen; Episode 13

The Invent Health weekly podcast with Dr. Archana Dubey and Bambi Francisco Roizen is the only weekly podcast that breaks down the latest digital health news of the week and what it means for patients, providers and payers (or who's paying). Plus a deep dive on a particular topic to help listeners understand how innovation is changing the healthcare paradigm. This week's deep dive: The Delta variation.

In this week's news portion: Path AI, which makes imaging tools to serve pathologists when they examine cells, buys Poplar Healthcare for an undisclosed amount. This demonstrates innovation in pathology. Poplar Healthcare has labs serving gastroenterologist, dermatologist, oncologists, urologists, and gynecologists. Most modernization has gone into blood tests but not biopsy, which is the examination of tissue removed from a body part, such as a pap smear. Data analytics company Komodo buys Breakaway Partners, which analyzes medical and Pharma claims data. The combination gives Komodo more data beyond electronic health records and other records from the health systems. Pharma. Happily Health roles out its first PDTx (prescription digital therapeutic) for depression and anxiety. Woebot closed a $90 million Series B, after receiving FDA Breakthrough Device Program.